Studies by He et al. suggest that PD-1 can inhibit cellular immunity, and the killing effect of TIL can be increased by blocking PD-1/PD-L1.15 Whether PD-L1 is positive in tumor micro-environment can be used as an indicator to judge the effect of immunotherapy.16 The gene discussed is CD274; the disease is neoplasm.